Provided by Tiger Trade Technology Pte. Ltd.

Valneva SE

5.48
-0.1900-3.35%
Post-market: 5.480.00000.00%16:10 EDT
Volume:36.90K
Turnover:206.53K
Market Cap:519.63M
PE:-3.00
High:5.93
Open:5.93
Low:5.40
Close:5.67
52wk High:12.25
52wk Low:5.06
Shares:94.82M
Float Shares:78.43M
Volume Ratio:0.90
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8266
EPS(LYR):-1.6084
ROE:-109.57%
ROA:-14.54%
PB:5.88
PE(LYR):-3.41

Loading ...

Valneva files to sell 31.79M ordinary shares for holders

TIPRANKS
·
Jun 05

Valneva Ramps Up June 2026 Investor and Medical Conference Presence

TIPRANKS
·
Jun 01

First Berlin reiterates Buy on Valneva, cuts price target to EUR 4.5

Reuters
·
May 28

Valneva (VALN) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Valneva SE reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Valneva Q1 EPS $(0.42) Misses $(0.21) Estimate, Sales $36.189M Miss $46.270M Estimate

Benzinga
·
May 13

Press Release: Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
May 13

Valneva SE expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
May 11

Valneva Sets May 13 Date to Present First-Quarter 2026 Results

TIPRANKS
·
May 06

Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone

TIPRANKS
·
May 01

Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50

MT Newswires Live
·
Apr 22

Federal Court Reportedly Halts Kennedy's Vaccine Panel, Putting COVID, Flu And RSV Shots At Risk

Benzinga_recent_news
·
Apr 21

Valneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington

TIPRANKS
·
Mar 27

Jefferies says Valneva stock weakness presents buying opportunity

TIPRANKS
·
Mar 24

Valneva Down Over 36%, on Pace for Largest Percent Decrease Since September 2021 -- Data Talk

Dow Jones
·
Mar 23

Top Premarket Decliners

MT Newswires Live
·
Mar 23

Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial

TIPRANKS
·
Mar 23

Pfizer: Co & Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor Trial

THOMSON REUTERS
·
Mar 23

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Reuters
·
Mar 23

Guggenheim Reaffirms Their Buy Rating on Valneva (VALN)

TIPRANKS
·
Mar 19